دورية أكاديمية
Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores.
| العنوان: | Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. |
|---|---|
| المؤلفون: | Ueki Y; Department of Cardiology, Bern University Hospital, Bern, Switzerland., Bär S, Losdat S, Otsuka T, Zanchin C, Zanchin T, Gragnano F, Gargiulo G, Siontis GCM, Praz F, Lanz J, Hunziker L, Stortecky S, Pilgrim T, Heg D, Valgimigli M, Windecker S, Räber L |
| المصدر: | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology [EuroIntervention] 2020 Aug 28; Vol. 16 (5), pp. 371-379. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Société Europa édition Country of Publication: France NLM ID: 101251040 Publication Model: Print Cited Medium: Internet ISSN: 1969-6213 (Electronic) Linking ISSN: 1774024X NLM ISO Abbreviation: EuroIntervention Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Toulouse : Société Europa édition, c2005- |
| مواضيع طبية MeSH: | AIDS-Related Complex* , Myocardial Infarction*, Percutaneous Coronary Intervention/*adverse effects, Hemorrhage/etiology ; Humans ; Platelet Aggregation Inhibitors ; Risk Factors |
| مستخلص: | Aims: The Academic Research Consortium for High Bleeding Risk (ARC-HBR) defined consensus-based criteria for patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). We aimed to validate the ARC-HBR criteria for the bleeding outcomes using a large cohort of patients undergoing PCI. Methods and Results: Between 2009 and 2016, patients undergoing PCI were prospectively included in the Bern PCI Registry. Patients were considered to be at HBR if at least one major criterion or two minor criteria were met. The primary endpoint was Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding at one year; ischaemic outcomes were assessed using the device-oriented composite endpoints (DOCE) of cardiac death, target vessel myocardial infarction, and target lesion revascularisation. Among 12,121 patients, those at HBR (n=4,781, 39.4%) had an increased risk of BARC 3 or 5 bleeding (6.4% vs 1.9%; p<0.001) and DOCE (12.5% vs 6.1%; p<0.001) compared with those without HBR. The degree of risk and prognostic value were related to the risk factors composing the criteria. The ARC-HBR criteria had higher sensitivity than the PRECISE-DAPT score and the PARIS bleeding risk score (63.8%, 53.1%, 31.9%), but lower specificity (62.7%, 71.3%, 86.5%) for BARC 3 or 5 bleeding. Conclusions: Patients at HBR defined by the ARC-HBR criteria had a higher risk of BARC 3 or 5 bleeding as well as DOCE. The bleeding risk was related to its individual components. The ARC-HBR criteria were more sensitive for identifying patients with future bleedings than other contemporary risk scores at the cost of specificity. ClinicalTrials.gov Identifier: NCT02241291 |
| سلسلة جزيئية: | ClinicalTrials.gov NCT02241291 |
| المشرفين على المادة: | 0 (Platelet Aggregation Inhibitors) |
| تواريخ الأحداث: | Date Created: 20200218 Date Completed: 20200924 Latest Revision: 20210607 |
| رمز التحديث: | 20240829 |
| DOI: | 10.4244/EIJ-D-20-00052 |
| PMID: | 32065586 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1969-6213 |
|---|---|
| DOI: | 10.4244/EIJ-D-20-00052 |